The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden

por Murphy, Daniel R, Smolen, Lee J, Klein, Timothy M, Klein, Robert W
Publicado 2012

Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States

por Furiak, Nicolas M, Ascher-Svanum, Haya, Klein, Robert W, Smolen, Lee J, Lawson, Anthony H, Conley, Robert R, Culler, Steven D
Publicado 2009